Navigation Links
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Date:3/17/2008

d greatly to our progress, and we wish them well in their future endeavors," continued Dr. Love.

Conference Call Information

Nuvelo will hold a conference call today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode, 39369496. A telephone replay of the conference call will be available through March 20, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode, 39369496.

In addition, this call is being webcast by Thomson/CCBN and can be accessed at Nuvelo's website at http://www.nuvelo.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to continue its research programs in leukemia and lym
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
3. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
4. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
5. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
6. Synbiotics Corporation Announces Human Submission for FluDetect(R)
7. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
8. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
9. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
10. Inclinix Announces New Patent for Expert System Platform
11. Genzyme Announces Presentation of New Positive Data on Carticel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... open letter to shareholders from President & CEO, ... Dear RXi Shareholders, In the ... posted on certain social media sites seem to ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... FORT LAUDERDALE, Fla., Nov. 27 Imaging,Diagnostic Systems, ... laser,optical breast imaging, announced today that the Company ... in its CTLM(R) clinical trials.,Under an approved protocol, ... submission of a Premarket Approval (PMA) application to ...
... 10:00 a.m. (EST), A World AIDS Day Call ... and African Women,s, Faith-based and Youth Rights,Organizations Call on Congress ... Plan, WASHINGTON, Nov. 26 The following was,released by ... November 29, 2007, at 10:00 a.m. EST, Who: ...
Cached Medicine Technology:Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System 2Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System 3World AIDS Day Audio Press Conference 2
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how this is an ... saying goes, “A picture says a thousand words.” It’s true. ... single image, because each picture holds a unique and special ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
(Date:12/24/2014)... iFitDress.com, a famous dress manufacturer and retailer, has announced ... these items are brand new; they are made by experienced ... the new range of high quality prom gowns. A lot ... are made according to the latest trends. For years, the ... the company is handpicked by skilled tailors. , In the ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. (Nasdaq: ... Syk inhibitor, R788, is being evaluated in a Phase ... National Cancer Institute (NCI), part of the U.S. National ... will include patients with advanced colorectal, thyroid, non-small cell ...
... Company to Divest Late Stage Operations, Signs ... INC Research, , , TORONTO, June 1 /PRNewswire-FirstCall/ - ... leading provider of products and services to the global life ... MDS Pharma Services business on the delivery of Early Stage ...
... June 1 A panoramic downtown Milwaukee view, ... to the rooftop healing garden at Aurora St. ... and sounds awaiting guests at the newly opened ... Agnes and Morland Hamilton Healing Conservatory. , ...
... ... Contacts ( www.ClearlyContacts.ca ) and Stockhouse ( www.Stockhouse.com ), are pleased to announce the ... ... 2009 -- Two Vancouver based online powerhouses, Clearly Contacts ( www.ClearlyContacts.ca ) and Stockhouse ...
... , ... regulations have forced healthcare providers, insurers, and managed care organizations to take a hard look ... industry now changes. Instead of "Do I accommodate the LEP market?" we are asking, "How ... , ...
... Infants and young toddlers with obstructive sleep apnea and ... of the ailment, according to an invited article in ... Surgery . , The study evaluated 73 cases in ... for obstructive sleep apnea through the removal of the ...
Cached Medicine News:Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa 2Health News:MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa 3Health News:MDS Announces Strategy to Focus MDS Pharma Services on Early Stage Operations - Discovery Through Phase IIa 4Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 2Health News:Aurora St. Luke's Dedicates Rooftop Healing Garden and Conservatory 3Health News:Clearly Contacts Forms Strategic Marketing Alliance with Stockhouse 2Health News:Clearly Contacts Forms Strategic Marketing Alliance with Stockhouse 3Health News:Avantpage Translations Releases White Paper on Capturing The Fastest Growing Healthcare Market In America 2
9 mm blade....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Duckbill. 3.5 mm tip. Light curve....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: